Dr. Matt and Dr. Mike's Medical Podcast Ozempic & Other GLP-1 Agonists
5 snips
Mar 28, 2026 A lively rundown of how GLP‑1 and GIP hormones shape insulin, appetite and digestion. They trace the science from gut hormones to drug discoveries like semaglutide and tirzepatide. Listeners hear about brain reward circuits, changing food preferences, and wider clinical effects beyond weight loss. The conversation also tackles side effects, perioperative issues, and ethical and societal implications.
AI Snips
Chapters
Books
Transcript
Episode notes
Drugs Target Central Appetite And Reward Circuits
- Pharmacological GLP-1 agonists engage hypothalamic and mesolimbic circuits to reduce hunger and alter food reward.
- Matthew Barton says drug levels are far higher than physiological, driving central appetite and reward changes.
Incretins Have Opposing Effects On Fat Cells
- GIP and GLP‑1 have opposing adipocyte actions: GIP promotes fat storage via lipoprotein lipase, while GLP‑1 promotes lipolysis via sympathetic activation.
- Together they may shift adipocytes toward a healthier, adiponectin‑rich phenotype.
Gila Monster Peptide Led To First GLP-1 Drug
- Exenatide originated from a GLP-1–like peptide found in the Gila monster and resisted DPP4 degradation.
- Matthew Barton recounts its development into Byetta, the first injectable GLP-1 therapy taken twice daily.
